News
REGN ▼ -3.2% - Regeneron Pharmaceuticals, Inc.
REGN ▼ -3.2% - Regeneron Pharmaceuticals, Inc.
$REGN - Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01-OCT-2026 11:30 AM ET
Share this post
More filings for $REGN
REGN ▼ -3.3% - Regeneron Pharmaceuticals, Inc.Oct 1, 2026REGN ▲ +1.1% - Regeneron Pharmaceuticals, Inc.Oct 1, 2026REGN ▼ -0.7% - Regeneron Pharmaceuticals, Inc.Sep 24, 2026
View full $REGN filing history →💬 Comments
Loading comments…
Leave a comment